EA199800104A1 - Способ лечения диабета - Google Patents

Способ лечения диабета

Info

Publication number
EA199800104A1
EA199800104A1 EA199800104A EA199800104A EA199800104A1 EA 199800104 A1 EA199800104 A1 EA 199800104A1 EA 199800104 A EA199800104 A EA 199800104A EA 199800104 A EA199800104 A EA 199800104A EA 199800104 A1 EA199800104 A1 EA 199800104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
treatment
type
obesity
patients
Prior art date
Application number
EA199800104A
Other languages
English (en)
Inventor
Томас В. Стефенз
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA199800104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800104A1 publication Critical patent/EA199800104A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Abstract

В изобретении описан способ лечения диабета страдающих ожирением больных диабетом II типа. В частности, заявлен способ лечения больных, страдающих ожирением с диабетом II типа, с изменяющимся уровнем эндогенного лептина.Отчет о международном поиске был опубликован 1997.05.22.
EA199800104A 1995-06-30 1996-06-26 Способ лечения диабета EA199800104A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71895P 1995-06-30 1995-06-30
PCT/US1996/010983 WO1997002004A2 (en) 1995-06-30 1996-06-26 Methods for treating diabetes

Publications (1)

Publication Number Publication Date
EA199800104A1 true EA199800104A1 (ru) 1998-10-29

Family

ID=21692725

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800104A EA199800104A1 (ru) 1995-06-30 1996-06-26 Способ лечения диабета

Country Status (14)

Country Link
US (1) US5756461A (ru)
EP (1) EP0836479A2 (ru)
JP (1) JPH11508895A (ru)
KR (1) KR19990028388A (ru)
CN (1) CN1195293A (ru)
AU (1) AU695934B2 (ru)
CA (1) CA2225454A1 (ru)
CZ (1) CZ416797A3 (ru)
EA (1) EA199800104A1 (ru)
HU (1) HUP9802609A2 (ru)
IL (1) IL122718A0 (ru)
NO (1) NO976063L (ru)
PL (1) PL324284A1 (ru)
WO (1) WO1997002004A2 (ru)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
ZA965346B (en) * 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
EP0759441A3 (en) * 1995-06-30 1999-06-30 Eli Lilly And Company Methods of treating neuropeptide Y-associated conditions
US6001816A (en) * 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
US6277592B1 (en) 1996-07-31 2001-08-21 Purina Mills, Inc. Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6956026B2 (en) * 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
BR9711513A (pt) * 1996-09-20 1999-08-24 Hoechst Ag Uso de antagonistas de leptina para o tratamento de resistencia a insulina em diabete do tipo ii
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
JP2002504102A (ja) * 1997-06-06 2002-02-05 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 糖尿病治療のためのレプチン拮抗物質の使用
WO1999006059A2 (en) * 1997-07-30 1999-02-11 Board Of Regents, The University Of Texas System Methods and compositions relating to no-mediated cytotoxicity
DE69824039T2 (de) 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US5866547A (en) * 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
JP4215857B2 (ja) * 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
EP1118001A1 (en) * 1998-10-02 2001-07-25 Amgen Inc. Method to determine a predisposition to leptin treatment
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
BR0207854A (pt) * 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
PL214862B1 (pl) * 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
US6899892B2 (en) * 2001-12-19 2005-05-31 Regents Of The University Of Minnesota Methods to reduce body fat
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP2390264A1 (en) 2005-02-11 2011-11-30 Amylin Pharmaceuticals Inc. GIP analog and hybrid polypeptides with selectable propperties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
ES2258923B1 (es) * 2005-02-23 2007-11-01 Universitat De Les Illes Balears Uso de la leptina para la prevencion del exceso de peso corporal y composicion que contiene leptina.
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
EP2352510A4 (en) * 2008-11-04 2012-08-29 Neurotez Inc LEPTIN COMPOSITIONS AND METHODS OF TREATING PROGRESSIVE COGNITIVE DISORDERS DUE TO THE ASSEMBLY OF NEUROFIBRILLARY BUNNELS AND AMYLOID BETA
JP2012523434A (ja) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ,インコーポレイテッド エストロゲン欠乏哺乳類のためのアミリンアゴニスト化合物
CN102552225A (zh) * 2010-01-25 2012-07-11 四川省中医药科学院 四氢姜黄素的新用途
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
ES2641869T3 (es) 2010-09-28 2017-11-14 Aegerion Pharmaceuticals, Inc. Polipéptidos de fusión de leptina-ABD con duración de acción aumentada
US10046013B2 (en) * 2011-03-08 2018-08-14 The Trustees Of The University Of Pennsylvania Engineered bacteria for oral delivery of glucoregulatory proteins
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof

Also Published As

Publication number Publication date
NO976063L (no) 1998-02-16
KR19990028388A (ko) 1999-04-15
CN1195293A (zh) 1998-10-07
IL122718A0 (en) 1998-08-16
PL324284A1 (en) 1998-05-11
NO976063D0 (no) 1997-12-23
AU6479596A (en) 1997-02-05
HUP9802609A2 (hu) 1999-03-29
EP0836479A2 (en) 1998-04-22
MX9800133A (es) 1998-03-29
CA2225454A1 (en) 1997-01-23
CZ416797A3 (cs) 1998-06-17
JPH11508895A (ja) 1999-08-03
WO1997002004A2 (en) 1997-01-23
US5756461A (en) 1998-05-26
AU695934B2 (en) 1998-08-27
WO1997002004A3 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
EA199800104A1 (ru) Способ лечения диабета
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
EP1231218A3 (en) An appetite-suppressing peptide, its compositions and use
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
DE69732868D1 (de) Mittel gegen Juckreiz
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
WO2000035436A3 (en) Treatment of arthritis with mek inhibitors
KR930703001A (ko) 전신 홍반성낭창의 치료방법
PT1333887E (pt) Metodo de tratamento de desordens musculares
EP0895781A3 (en) Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
DK0775007T3 (da) Blodbehandlingsindretning med forbedret udbytte, og som har en vinklet grænsestyreflade
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
DE60139466D1 (de) Behandlung von diabetes
TR199900056T2 (xx) Leptin direncinin yeni tedavisi.
IT8323509A0 (it) Procedimento per trattare riso con pula unita ad esso e riso greggio, nonche' riso trattato con esso ottenuto.
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
ATE246924T1 (de) Neue therapeutische verwendung von nicergoline
NO982582L (no) Fremgangsmaate for behandling av smerte
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
NL192620B (nl) Putbehandelingsvloeistoffen.
DE68913995T2 (de) Zusammensetzung zur behandlung progressiver myopie.
EA199700449A1 (ru) Способ предотвращения остеопороза
EA199800822A1 (ru) Способ лечения избыточной агрессии
NO20012849D0 (no) Ny terapeutisk anvendelse for hepariner med lav molekylvekt
DE69910608D1 (de) Neue therapeutische verwendung von 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin